emerging technologies

Recent Articles

Genomics Has Revealed An Age Undreamed Of

BY RAZIB KAHN
PALLADIUM MAGAZINE

On June 26, 2000, President Bill Clinton announced the completion of the draft of the human genome at a press conference with the two project leads, Francis Collins and J. Craig Venter. A genome is all the genetic information of an organism. Scientists had conceived of the Human Genome Project in the 1980s, and, in the first half of the 1990s, expected it to be an endeavor that would go on for decades. But an unexpected technological revolution of faster computers and better chemistry accelerated the ten-year effort toward the finish line, just as the 20th century came to a close. Continue Reading →

Filed under:

Blood test spots multiple cancers without clear symptoms, study finds

BY IAN SAMPLE
THE GUARDIAN

Doctors have told health services to prepare for a new era of cancer screening after a study found a simple blood test could spot multiple cancer types in patients before they develop clear symptoms.

The Pathfinder study offered the blood test to more than 6,600 adults aged 50 and over, and detected dozens of new cases of disease. Many cancers were at an early stage and nearly three-quarters were forms not routinely screened for.

It is the first time results from the Galleri test, which looks for cancer DNA in the blood, have been returned to patients and their doctors, to guide cancer investigations and any necessary treatment. Continue Reading →

Filed under:

CRISPR gene editing therapy for HIV is heading into human testing after FDA clearance

BY ANNALEE ARMSTRONG
FIERCE BIOTECH

A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing.

Excision BioTherapeutics will usher the CRISPR-based therapy EBT-101 into clinical trials after the FDA cleared an investigational new drug application, according to the company’s press release.

EBT-101 is under development as a potential virus-clearing treatment for patients with HIV—or, put in the company’s words, “a potential functional cure for chronic HIV.”

We don’t like to throw the word “cure” around here. But Excision thinks the therapy could replace standard-of-care retroviral therapy, which keeps HIV from replicating but does not remove it from the body. That means patients stay on the treatment, which can cause serious side effects and affect quality of life. Now with the start of human testing, the real path to see if this new and lauded tech can accomplish this really begins.

HIV integrates its genetic material into the genome of a host cell, meaning available therapies just can’t remove it. A team of scientists at Temple University and the University of Nebraska Medical Center managed to remove the virus completely from mice during preclinical testing using a combination of CRISPR and antiretroviral therapy. They also found no adverse events that could be linked to the therapy in the study, published back in 2019.

“If you just make a single cut, the virus can mutate around it. We make multiple cuts to deactivate the viral genome,” CEO Daniel Dornbusch previously told Fierce Biotech in an interview.

EBT-101 has since been tested in nonhuman primates, which showed it reached every tissue in the body where HIV reservoirs reside.

Excision licensed the therapy from the universities with a goal of moving it into clinical trials. Now, the FDA is on board.

The biotech plans to initiate a phase 1/2 clinical trial later this year, according to the statement.

The technology used by Excision was licensed from the lab of famed CRISPR pioneer Jennifer Doudna. The company is also working on similar treatments for other viruses, including herpes and hepatitis B.

Excision’s news arrives the same week that Intellia announced a gene editing therapy for acute myeloid leukemia had been cleared for human trials by the FDA. Continue Reading →

Filed under:

First genetically modified mosquitoes released in the United States

BY EMILY WALTZ
NATURE
After a decade of fighting for regulatory approval and public acceptance, a biotechnology firm has released genetically engineered mosquitoes into the open air in the United States for the first time. The experiment, launched this week in the Florida Keys — over the objections of some local critics — tests a method for suppressing populations of wild Aedes aegypti mosquitoes, which can carry diseases such as Zika, dengue, chikungunya and yellow fever. Continue Reading →

Filed under:

This microbe no longer needs to eat food to grow, thanks to a bit of genetic engineering

BY ROBERT F SERVICE
SCIENCE MAGAZINE
Synthetic biologists have performed a biochemical switcheroo. They’ve re-engineered a bacterium that normally eats a diet of simple sugars into one that builds its cells by absorbing carbon dioxide (CO2), much like plants. The work could lead to engineered microbes that suck CO2 out of the air and turn it into medicines and other high-value compounds. Continue Reading →

Filed under:

The world’s first Gattaca baby tests are finally here

BY ANTONIO REGALADO
MIT TECHNOLOGY REVIEW
Anxious couples are approaching fertility doctors in the US with requests for a hotly debated new genetic test being called “23andMe, but on embryos.”

The baby-picking test is being offered by a New Jersey startup company, Genomic Prediction, whose plans we first reported on two years ago.

The company says it can use DNA measurements to predict which embryos from an IVF procedure are least likely to end up with any of 11 different common diseases. In the next few weeks it’s set to release case studies on its first clients. Continue Reading →

Filed under:

SickKids scientist calls for ‘national strategy’ to get genome sequencing covered in Canada

BY GENNA BUCK
NATIONAL POST
Whole-genome sequencing is not available in Canada yet under any provincial health plan. But Ontario’s health-care quality agency is currently reviewing a proposal to cover it for children with unexplained developmental delay, said Wendy Ungar, director of technology assessment at Toronto’s SickKids hospital, a major Canadian centre for this area of research. Continue Reading →

Filed under:

World’s first living organism with fully redesigned DNA created

BY IAN SAMPLE
THE GUARDIAN

Scientists have created the world’s first living organism that has a fully synthetic and radically altered DNA code.

The lab-made microbe, a strain of bacteria that is normally found in soil and the human gut, is similar to its natural cousins but survives on a smaller set of genetic instructions.

The bug’s existence proves life can exist with a restricted genetic code and paves the way for organisms whose biological machinery is commandeered to make drugs and useful materials, or to add new features such as virus resistance.

In a two-year effort, researchers at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge read and redesigned the DNA of the bacterium Escherichia coli (E coli), before creating cells with a synthetic version of the altered genome.

The artificial genome holds 4m base pairs, the units of the genetic code spelled out by the letters G, A, T and C. Printed in full on A4 sheets, it runs to 970 pages, making the genome the largest by far that scientists have ever built.

“It was completely unclear whether it was possible to make a genome this large and whether it was possible to change it so much,” said Jason Chin, an expert in synthetic biology who led the project.

The DNA coiled up inside a cell holds the instructions it needs to function. When the cell needs more protein to grow, for example, it reads the DNA that encodes the right protein. The DNA letters are read in trios called codons, such as TCG and TCA.

Nearly all life, from jellyfish to humans, uses 64 codons. But many of them do the same job. In total, 61 codons make 20 natural amino acids, which can be strung together like beads on a string to build any protein in nature. Three more codons are in effect stop signs: they tell the cell when the protein is done, like the full stop marking the end of this sentence.

The Cambridge team set out to redesign the E coli genome by removing some of its superfluous codons. Working on a computer, the scientists went through the bug’s DNA. Whenever they came across TCG, a codon that makes an amino acid called serine, they rewrote it as AGC, which does the same job. They replaced two more codons in a similar way.

More than 18,000 edits later, the scientists had removed every occurrence of the three codons from the bug’s genome. The redesigned genetic code was then chemically synthesised and, piece by piece, added to E coli where it replaced the organism’s natural genome. The result, reported in Nature, is a microbe with a completely synthetic and radically altered DNA code. Known as Syn61, the bug is a little longer than normal, and grows more slowly, but survives nonetheless.

“It’s pretty amazing,” said Chin. When the bug was created, shortly before Christmas, the research team had a photo taken in the lab with a plate of the microbes as the central figure in a recreation of the nativity.

Such designer lifeforms could come in handy, Chin believes. Because their DNA is different, invading viruses will struggle to spread inside them, making them in effect virus-resistant. That could bring benefits. E coli is already used by the biopharmaceutical industry to make insulin for diabetes and other medical compounds for cancer, multiple sclerosis, heart attacks and eye disease, but entire production runs can be spoiled when bacterial cultures are contaminated with viruses or other microbes. But that is not all: in future work, the freed-up genetic code could be repurposed to make cells churn out designer enzymes, proteins and drugs.

In 2010, US scientists announced the creation of the world’s first organism with a synthetic genome. The bug, Mycoplasma mycoides, has a smaller genome than E coli – about 1m base pairs – and was not radically redesigned. Commenting on the latest work, Clyde Hutchison, from the US research group, said: “This scale of genome replacement is larger than any complete genome replacement reported so far.”

“They have taken the field of synthetic genomics to a new level, not only successfully building the largest ever synthetic genome to date, but also making the most coding changes to a genome so far,” said Tom Ellis, a synthetic biology researcher at Imperial College London.

But the records may not stand for long. Ellis and others are building a synthetic genome for baker’s yeast, while Harvard scientists are making bacterial genomes with more coding changes. That the redesigned E coli does not grow as well as natural strains is not surprising, Ellis added. “If anything it’s surprising it grows at all after so many changes,” he said.

Continue Reading →

Filed under:

Scientists may have found a way to treat cancer without chemotherapy by replicating our body’s own self-destruct system

BY LISA SCHONHAAR
BUSINESS INSIDER
Every day, millions of cells in our bodies “kill” themselves and are quickly removed.
While the mechanism may sound dramatic, it’s for our own good. The process ensures that potentially harmful cells destroy themselves and protects us from diseases.
Cancer cells, however, can protect themselves from self-destruction by ignoring our immune system’s cell-death signals — and that’s precisely what makes them so dangerous.
Continue Reading →

Filed under: